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Introduction
High-dose estrogen was the endocrine treatment of
choice in postmenopausal women with advanced breast
cancer prior to the introduction of tamoxifen in the 1970s.
Cole et al. reported the first clinical trial of tamoxifen in
women with late or recurrent breast cancer [1], and com-
pared their findings with those from another similarly con-
ducted trial in which women received diethylstilbestrol
(DES) or an androgen. They concluded that the level of
response was of the same order for the three agents but
that an advantage for tamoxifen was the low incidence of
‘troublesome side effects’.
Consistent with these early findings, the acceptance of
tamoxifen as preferable to estrogen therapy was based
not on a superior efficacy, but rather on an improved toler-
ability demonstrated in phase III trials [2,3]. It is common
practice to employ a series of endocrine agents in patients
who remain candidates for such therapy on the basis of
sites, extent, and tempo of disease and clinical status. It is
remarkable given the prior importance of estrogens that,
following the establishment of tamoxifen as the standard,
estrogens largely disappeared from the endocrine therapy
mindset of practicing oncologists, being relegated to the
end of a list of agents that included aromatase inhibitors
(AIs), progestins, and androgens.
We have recently updated our trial of DES versus tamoxifen.
Although the trial is small in size by today’s standards, it pro-
vided mature survival data in that 95% of the 143 eligible
patients had died [4]. There was no significant difference
between the two agents in terms of response rates and time
to progression. However, survival was modestly and signifi-
cantly better for women initially treated with DES (adjusted
P= 0.039), with median survivals of 3.0 years versus
2.4 years, and 5-year survivals of 35% and 16%, respectively.
Estrogen as salvage endocrine therapy
A recent report by Lønning et al. described the use of
high-dose DES in women with prior endocrine exposure
[5]. This was a prospective phase II clinical trial that used
well-established (Union Internationale Contre le Cancer)
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criteria for patient assessment. Eligibility criteria included a
requirement for evidence of endocrine sensitivity as indi-
cated by a prior response or 6 months of disease stability
on an endocrine agent.
Thirty-two patients were entered in the trial with a median
of four prior endocrine regimens (range, two to 10 regi-
mens). Three or more endocrine regimens had been
employed in almost all (i.e. 29) of the patients, and 20
patients (62%) had also received prior chemotherapy.
This population of patients can thus be considered heavily
pretreated. Considering hormonal receptor status, one-
quarter had either estrogen receptor-negative and proges-
terone receptor-negative tumors (two patients), or the
receptors were unknown (six patients). From the stand-
point of patient outcomes, it is remarkable that 10 patients
(31%) achieved either a complete response (four patients,
12%) or a partial response (six patients, 19%), with one-
half of these responses lasting for longer than 1 year.
Although all but two patients had the responses in ‘local
regional’ disease, the longest responder (>124 weeks)
was a patient with visceral metastasis.
The fact that high-dose estrogens are not tolerable in all
patients is illustrated by the fact that six patients (19%)
stopped therapy because of side effects. This proportion
is of the same order as our experience in the first-line
treatment setting [2], where nine out of 74 patients (12%)
discontinued DES because of side effects. It has become
the present author’s experience that a step-wise escala-
tion of the estrogen dose over 1–2 weeks, and in some
cases longer, will ameliorate the toxicity and make the
treatment tolerable. A previous report also identified effi-
cacy for DES in a smaller group of 11 patients, in whom all
but one had received at least two prior therapies and four
achieved a complete response or a partial response [6].
Interpreting the Lønning et al. estrogen trial
Care must be taken in attempting to place the results of
the Lønning et al. phase II trial [5] in the proper context
because this involves the perilous process of cross-study
comparisons. This is particularly the case when utilizing
the parameter of response rate, as this can be greatly
modulated by patient selection. Some observations are
possible, however, regarding levels of response seen with
the most efficacious endocrine agents available today,
albeit in less heavily pretreated patient populations.
Two trials evaluated third-generation AIs in patients who
had disease progression after tamoxifen and megestrol
acetate. Jones et al. evaluated the steroidal AI exemestane
in 91 patients and identified a response rate (complete
response + partial response) of 13% [7]. Letrozole was
evaluated in a similar population and in 45 patients treated
at the recommended dose of 2.5 mg/day; the response
rate was 18% using different criteria [8].
Two studies have also evaluated exemestane but in
patients who had prior nonsteroidal AI exposure. Thürli-
mann et al. studied exemestane at 200 mg/day, which is
eight times the recommended dose, in 78 patients with
progressive disease on aminoglutethimide, and with most
patients also on tamoxifen [9]. They found a response
rate of 26%. Lønning et al. used the currently recom-
mended dose of 25 mg/day in a large phase II trial of
exemestane in 241 patients [10]. The prior AI in this
study had been a third-generation, nonsteroidal agent
(anastrozole, letrozole, or vorozole) in 44% of patients,
with the remainder having received prior aminog-
lutethimide. Three-quarters of the patients had received
two prior endocrine agents, and 22% had received three
prior endocrine agents. The response rate was more
modest in this trial, being 6.2%.
In a second-line endocrine therapy setting in patients
having received prior tamoxifen, the response rates
observed for the third-generation AIs anastrozole,
exemestane, and letrozole were 10% [11], 15% [12], and
24% [13], respectively. These rates were observed in
phase III studies in comparison with megestrol acetate.
The 31% objective response rate observed in the Lønning
et al. trial with DES [5] is thus remarkable and encourag-
ing even considering all the cautionary caveats regarding
interpretation of a small phase II trial.
Resistance to endocrine therapy
The mechanisms by which a patient’s cancer becomes
resistant to endocrine therapy are poorly understood.
Insights into potential mechanisms come from the work of
Masamura et al. [14], who hypothesized that the response
observed to subsequent endocrine therapy could be
related to increased sensitivity to estradiol (E2), due to
adaptation by tumor cells to E2 deprivation. These investi-
gators grew MCF-7 cells in serum-free medium to elimi-
nate E2, and these cells were designated long-term
estrogen-deprived (LTED) cells.
When the E2 dose–response curve was generated, a
typical bell-shaped curve was seen with an initial increase
in stimulation at lower doses, a peak stimulation, and a
progressive diminution in stimulation at higher E2 concen-
trations. The LTED cells showed maximal stimulation at
10–14 mol/l E2. This represented a shift to the left in the
dose–response curve, in that the curve for the wild-type
MCF-7 cells had maximal stimulation of 10–10 mol/l, which
represents a 10,000-fold higher concentration compared
with the LTED cells.
Masamura et al. also studied the concentration of a pure
antiestrogen (ICI 164384) necessary to inhibit growth by
50%. They found that it was substantially lower in the
LTED cells (10–15 mol/l) than in the wild-type MCF-7 cells
(10–9 mol/l).135
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The results of these studies provide a potential explana-
tion for loss of efficacy of agents that act to lower or block
E2. The explanation is that the breast cancer cells can
adjust to the agent-induced lower E2 environment by
becoming more sensitive to a given E2 concentration.
Use of a shifting estrogen dose–response
curve for therapeutic purposes
One can hypothesize from the preceding discussion that,
in the clinical setting, long-term estrogen deprivation could
shift the estrogen dose–response curve of a tumor to the
left and increase the sensitivity to estrogen therapy. In
considering this hypothesis, a case from the author’s clinic
is of note.
A 62-year-old patient was diagnosed with estrogen recep-
tor-positive stage I breast cancer and was given adjuvant
tamoxifen. The patient developed metastatic disease
2 years later, which was treated for more than 1 year with
a third-generation nonsteroidal AI and then with a steroidal
AI without response. On subsequent progression, the
patient elected another endocrine trial. The patient
received high-dose estrogen and achieved almost com-
plete clearing of pleural metastasis, which has been main-
tained for longer than 1 year.
It is plausible that the year-long treatment with AIs repre-
sents the clinical equivalent of long-term estrogen depriva-
tion seen in the laboratory. The third-generation AIs such
as letrozole and anastrozole are potent, and they have
been found to substantially suppress total-body aromatiza-
tion (>99.1% and 97.3%, respectively) and plasma E2
levels (87.8% and 84.9%, respectively) [15].
The clinical observations combined with the laboratory data
noted earlier support further study of high-dose estrogen
following maximal estrogen deprivation in appropriately
selected patients.
Song et al. studied LTED and wild-type MCF-7 cells with
regard to the potential mechanism of action of high-dose
estrogen [16]. Apoptosis was induced by high concentra-
tions (≥0.1 nM) of E2 in LTED cells, with a sevenfold
increase over vehicle-treated controls and a concomitant
60% decrease in growth, but not in wild-type MCF-7 cells.
The authors presented data showing that only LTED cells
expressed Fas protein, and they suggested that high-dose
estrogen may induce tumor regressions in postmenopausal
women through activation of Fas-mediated apoptosis.
Clinical responses to a wide range of estrogen doses
have been seen in breast cancer. Responses to DES in a
double-blind, randomized clinical trial were observed over
a 3-log range from 1.5 to 1500 mg daily [17]. Substantial
tumor regressions have been seen with even relatively
minor modifications in estrogen levels, as in withdrawal of
physiologic estrogen replacement [18]. Howell addressed
the issue of a shifting estrogen dose–response curve in a
patient’s tumor [19] and discussed potential strategies of
preventing resistance such as fixed alternating endocrine
therapies and stepwise modifications of estrogen levels.
Conclusions
The use of high-dose estrogen as therapy in selected
patients with metastatic breast cancer and prior endocrine
exposure has merit, based on the efficacy demonstrated in
a prospective clinical trial conducted by Lønning et al. [5].
Although the potential for toxicity exists with estrogen
therapy, the tolerability in the majority of patients is better
than with chemotherapy.
There are important implications of these clinical data
when considered in conjunction with recent laboratory
findings related to shifting of estrogen dose–response
curves for breast cancer cells with alterations of the hor-
monal environment. Together, they suggest testable
hypotheses of management strategies that have the
potential for increasing the value of endocrine therapy for
women with breast cancer.
References
1. Cole MP, Jones CTA, Todd IDH: A new anti-oestrogenic agent
in late breast cancer. An early clinical appraisal of ICI46474.
Br J Cancer 1971, 25:270-275.
2. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols
LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Ran-
domized clinical trial of diethylstilbestrol versus tamoxifen in
postmenopausal women with advanced breast cancer. N Engl
J Med 1981, 304:16-21.
3. Stewart HJ, Forrest APM, Gunn JM, Hamilton T, Langlands AO,
McFadyen IJ, Roberts MM: The tamoxifen trial: a double-blind
comparison with Stilboestrol in postmenopausal women with
advanced breast cancer. In  Breast Cancer: Experimental and
Clinical Aspects. Edited by Mouridsen HT, Palshof T. Oxford:
Pergamon Press; 1980:83-88.
4. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi
CL:  Randomized trial of diethylstilbestrol vs. tamoxifen in
postmenopausal women with metastatic breast cancer. An
updated analysis. Breast Cancer Res Treat 1999, 54:117-122.
5. Lønning PE, Taylor PD, Anker G, Iddon J, Wie L, Jørgensen L-M,
Mella O, Howell A: High-dose estrogen treatment in post-
menopausal breast cancer patients heavily exposed to
endocrine therapy. Breast Cancer Res Treat 2001, 67:111-116.
6. Boyer MJ, Tattersall MHN: Diethylstilbestrol revisted in
advanced breast cancer management. Med Pediatr Oncol
1990, 18:317-320.
7. Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P,
Cooper B, Honig S, Polli A, Whaley F, di Salle E, Tiffany J,
Consonni A, Miller L: Multicenter, phase II trial of exemestane
as third-line hormonal therapy of postmenopausal women
with metastatic breast cancer. J Clin Oncol 1999,  17:3418-
3425.
8. Ingle JN, Johnson PA, Suman VJ, Gerstner JB, Mailliard JA,
Camoriano JK, Gesme DH, Loprinzi CL, Hatfield AK, Hartmann
LC:  A randomized phase II trial of two dosage levels of
letrozole as third-line hormonal therapy for women with
metastatic breast carcinoma. Cancer 1997, 80:218-224.
9. Thürlimann B, Paridaens R, Serin D, Bonneterre J, Roche H,
Murray R, di Salle E, Lanzalone S, Zurlo MG, Piscitelli G: Third-
line hormonal treatment with exemestane in postmenopausal
patients with advanced breast cancer progressing on
aminolugtethimide: a phase II multicentre, multinational
study. Eur J Cancer 1997, 33:1767-1773.136
Breast Cancer Research    Vol 4 No 4 Ingle
10. Lønning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD,
Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C,
Arkhipov A, di Salle E, Polli A, Massimini G: Activity of exemes-
tane in metastatic breast cancer after failure of nonsteroidal
aromatase inhibitors. J Clin Oncol 2000, 18:2234-2244.
11. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL,
Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV: Anas-
trozole, a potent and selective aromatase inhibitor, versus
megestrol acetate in postmenopausal women with advanced
breast cancer: results of overview analysis of two phase III
trials. Arimidex Study Group. J Clin Oncol 1996, 14:2000-2011.
12. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N,
Dugardyn J-L, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A,
di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G:
Exemestane is superior to megestrol acetate after tamoxifen
failure in postmenopausal women with advanced breast
cancer: results of a phase III randomized double-blind trial.
J Clin Oncol 2000, 18:1399-1411.
13. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L,
Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M,
Fornasiero A, Hoffman W, Michel J, Hatschek T, Tjabbes T,
Chaudri HA, Hornberger U, Trunet PF: Letrozole, a new oral
aromatase inhibitor for advanced breast cancer: double-blind
randomized trial showing a dose effect and improved efficacy
and tolerability compared with megestrol acetate. J Clin Oncol
1998, 16:453-461.
14. Masamura S, Santner SJ, Heitjan DF, Santen RJ: Estrogen depri-
vation causes estradiol hypersensitivity in human breast
cancer cells. J Clin Endocrinol Metab 1995, 80:2918-2925.
15. Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE: Influence
of letrozole and anastrozole on total body aromatization and
plasma estrogen levels in postmenopausal breast cancer
patients evaluated in a randomized, cross-over study. J Clin
Oncol 2002, 20:751-757.
16. Song RX-D, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z,
Yue W, Wang J, Santen RJ: Effect of long-term estrogen depri-
vation on apoptotic responses of breast cancer cells to 17β β-
estradiol. J Natl Cancer Inst 2001, 93:1714-1723.
17. Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley
RW, Potter NR: Diethylstilbestrol: recommended dosages for
different categories of breast cancer patients. JAMA 1977,
237:2079-2085.
18. Dhodapkar MV, Ingle JN, Ahmann DL: Estrogen replacement
therapy withdrawal and regression of metastatic breast
cancer. Cancer 1995, 75:43-46.
19. Howell A: Future use of selective estrogen receptor modula-
tors and aromatase inhibitors. Clin Cancer Res 2001,  7
(suppl):4402s-4410s.